


Organisers



Co-Sponsors



The World Health Organization, Unitaid and the Medicines Patent Pool, together with the governments of South Africa and France and the Global Fund to Fight AIDS, Tuberculosis and Malaria, are honoured to invite you to a satellite symposium during **the 9th International AIDS Society Conference on HIV Science:**

ACCELERATING ACCESS TO NEW HIV MEDICINES IN LOW- AND MIDDLE-INCOME COUNTRIES

Tuesday 25 July 2017

From 18:30 to 20:30

Maillot Room

Convention Centre, 2 Place de Porte Maillot, 75017 Paris, France

A light reception will be served after the symposium

New antiretrovirals (ARVs) and formulations have the potential of revolutionising adult and paediatric HIV treatment. However, their introduction and scale-up in low- and middle-income countries can be complex and take significant time. The satellite symposium will review new ARVs and new formulations, analyse the range of different challenges that need to be overcome to ensure rapid scale-up and discuss initiatives that are contributing to accelerating development, registration and access. Particular attention will be devoted to addressing regulatory challenges and existing programmes and initiatives to facilitate and speed in-country registration and market introduction.

ACCELERATING ACCESS TO NEW HIV MEDICINES IN LOW- AND MIDDLE-INCOME COUNTRIES

PROGRAMME

Welcome Remarks - **Michèle Boccoz**, HIV/AIDS Ambassador, France

Co- Chairs: **Greg Perry**, Executive Director, Medicines Patent Pool (MPP) and
Michèle Boccoz, HIV/AIDS Ambassador, France



Opening Presentations – Setting the Scene and Identifying Needs, Opportunities and Hurdles

- Need for timely access to new and appropriate HIV medicines in low- and middle-income countries - **Tapiwanashe Kujinga**, Member, AfroCAB
- Analysis of products in the pipeline, new formulations and future opportunities - **Robert Matiru**, Director of Operations, Unitaid
- MPP licences and opportunities for introduction of new products and formulations - **Esteban Burrone**, Head of Policy, MPP
- Clinical significance of the new ARV formulations and possible challenges for transitioning - **Marco Vitoria**, Medical Officer, WHO HIV/AIDS Department and Global Hepatitis Programme
- Challenges and opportunities in the development, registration and uptake of new formulations - **Helen McDowell**, Director, Government Affairs, Access & Patients Advocacy, ViiV Healthcare
- Challenges and opportunities in the development, registration and uptake of new formulations and combinations - **Umesh K**, Vice President and Business Unit Head - Antivirals, Aurobindo

Roundtable Panel - Identifying Solutions

Co- Chairs: **Greg Perry**, MPP and **Marco Vitoria**, WHO

- WHO Prequalification Programme - **Emer Cooke**, Head of Regulation of Medicines and other Health Technologies, WHO Department of Essential Medicines and Health Products
- National Department of Health of South Africa - **Anban Pillay**, Deputy Director General, Health Financing and Economics
- Clinton Health Access Initiative (CHAI) - **Caroline Middlecote**, Associate Director, HIV Access Programme
- The Global Fund to Fight AIDS, Tuberculosis and Malaria - **Martin Auton**, Manager, Global Sourcing
- ICAP at Columbia University - **Elaine Abrams**, Senior Research Director

Q&A Session

Closing Remarks - **Lelio Marmora**, Executive Director, Unitaid